NeutralMRKMerckMerckMRNAModernaModerna

2w ago on

#ESMO Oncologists, if you don’t demand that neoantigen vaccines be studied against NEOadjuvant therapy, you’re doing the world and your patients a major disservice. It’s not $MRK or $MRNA’s fault that the standard of care evolved after their study was launched, but we cannot reward “innovation” with tens of billions of dollars when that “innovation” might be replaced by simply giving the first 2-3 doses of medicine sooner, FOR ABSOLUTELY FREE. This is ridiculous.

MRKMerckNeutralMerckMRNAModernaBearishModerna

2w ago on

$MRNA with the single most hilarious possible outcome in this study. EFS HR 0.58. Down the the hundredth, EXACTLY what *NEO*-adjuvant treatment with pembro yielded against adjuvant pembro (the nerfed comparator $MRNA studied against) in SWOG S1801. What does this mean in English? $MRNA’s drug is showing the exact same benefit versus adjuvant pembrolizumab as NEOadjuvant pembrolizumab did. Even more simply? If you just give patients a few doses of the pembrolizumab BEFORE you cut their cancer out, you do what $MRNA does for you, except with just the free tumor that’s already inside your body. No need to pay for this $400K drug. And this makes rational sense, right? The whole point of $MRNA’s vaccine is to produce stuff that looks like the tumor. You know what looks A LOT like the tumor does? THE FREAKING TUMOR!!!!!! Absolutely poetic that $MRNA produced the EXACT HR benefit as neoadjuvant pembro did. Truly, the most hilarious possible outcome. Now can we move on from this bullshit? $MRK and $MRNA should feel free to study their vaccine against the REAL standard of care now - NEOadjuvant immunotherapy. From my perspective, this has been total fugaze, and an amateurish pump and dump worthy of much lesser enterprises.